Tue, 10 Feb 2026 11:16:53 GMT
AstraZeneca FY 2025 Results: Revenue and FY 2026 Growth Forecast
AstraZeneca reported a gross margin of 80% for FY 2025, down 2 points due to profit-sharing on medicines like Lynparza and Enhertu, a $235 million royalty buyout for Saphnelo and rilvegostomig, and US pricing adjustments. Reported operating profit rose 37% to $13.7 billion, while Core operating profit grew 9% to $18.5 billion, reflecting adjustments for intangible asset amortization and impairments.